+

WO2003005034A3 - Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene - Google Patents

Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene Download PDF

Info

Publication number
WO2003005034A3
WO2003005034A3 PCT/CA2002/001004 CA0201004W WO03005034A3 WO 2003005034 A3 WO2003005034 A3 WO 2003005034A3 CA 0201004 W CA0201004 W CA 0201004W WO 03005034 A3 WO03005034 A3 WO 03005034A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
agents useful
processes
treating diseases
diseases involving
Prior art date
Application number
PCT/CA2002/001004
Other languages
French (fr)
Other versions
WO2003005034A2 (en
Inventor
Marcia L Macdonald
Jutta M Zeisler
Mark Samuels
Yigal P Goldberg
Johanne M Robataille
Michael R Hayden
Original Assignee
Xenon Genetics Inc
Univ British Columbia
Marcia L Macdonald
Jutta M Zeisler
Mark Samuels
Yigal P Goldberg
Johanne M Robataille
Michael R Hayden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Genetics Inc, Univ British Columbia, Marcia L Macdonald, Jutta M Zeisler, Mark Samuels, Yigal P Goldberg, Johanne M Robataille, Michael R Hayden filed Critical Xenon Genetics Inc
Publication of WO2003005034A2 publication Critical patent/WO2003005034A2/en
Publication of WO2003005034A3 publication Critical patent/WO2003005034A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mutations in selected genes, such as the Frizzled-4 gene ('fzd4'), which are causative agents in hereditary human visual disorders, such as familial exudative vitreoretinopathy ('FEVR'), are disclosed along with methods of use, including assays for therapeutic agents useful in treating such diseases and/or ameliorating their effects as well as methods of diagnosing conditions of visual impairment caused by mutations in these genes.
PCT/CA2002/001004 2001-07-05 2002-07-04 Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene WO2003005034A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30328501P 2001-07-05 2001-07-05
US60/303,285 2001-07-05
US34040901P 2001-10-29 2001-10-29
US60/340,409 2001-10-29

Publications (2)

Publication Number Publication Date
WO2003005034A2 WO2003005034A2 (en) 2003-01-16
WO2003005034A3 true WO2003005034A3 (en) 2003-05-30

Family

ID=26973372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001004 WO2003005034A2 (en) 2001-07-05 2002-07-04 Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene

Country Status (1)

Country Link
WO (1) WO2003005034A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025590A2 (en) * 2003-09-15 2005-03-24 Develogen Aktiengesellschaft Use of a dg280 protein product for preventing and treating metabolic disorders
DE102004050620A1 (en) * 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoclonal antibody against Frizzled receptors
AU2005318086B2 (en) * 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
EP2491143B1 (en) * 2009-10-21 2017-12-13 Retinal Solutions LLC Methods and compositions for diagnosis and treatment of genetic and retinal disease
CN118440947B (en) * 2024-07-08 2024-09-06 湖南家辉生物技术有限公司 FZD4 gene mutant, mutant protein and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (en) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
WO1999026960A2 (en) * 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
EP1001023A2 (en) * 1998-09-09 2000-05-17 Smithkline Beecham Plc Frizzled-4, a putative Wnt-receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (en) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University Wnt RECEPTOR COMPOSITIONS AND METHODS
WO1999026960A2 (en) * 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
EP1001023A2 (en) * 1998-09-09 2000-05-17 Smithkline Beecham Plc Frizzled-4, a putative Wnt-receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIRIKOSHI H ET AL: "MOLECULAR CLONING AND CHARACTERIZATION OF HUMAN FRIZZLED-4 ON CHROMOSOME 11Q14-Q21", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 264, no. 3, 2 November 1999 (1999-11-02), pages 955 - 961, XP001057078, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2003005034A2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
WO2003004045A3 (en) Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
HK1112941A1 (en) Use of a33 antigens and jam-it a33
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
AU2002366641A1 (en) Methods for inhibiting ocular processes
WO2006125830A3 (en) Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2004063340A3 (en) Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4
WO2003005034A3 (en) Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2003038130A3 (en) Therapeutics and diagnostics for disorders of erythropoiesis
WO2003050504A3 (en) Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
MXPA03010728A (en) B7 related protein-2 molecules and uses thereof.
WO2006047544A3 (en) Compositions and methods for treating alzheimer’s disease and related disorders and promoting a healthy nervous system
WO2003026566A3 (en) Atlastin
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
WO2004005540A3 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
WO2008070284A3 (en) Amyloid beta peptides and methods of uses thereof
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载